GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC | MicrobiomeTrials← Back to trialsNCT04864054
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-03-11Est. Completion: 2027-12-31
Enrollment target: 60 participants Locations- City of Hope, Duarte, California, United States
- Kansas University Medical Center, Principal Investigator:, Westwood, Kansas, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Montefiore Einstein Comprehensive Cancer Center, The Bronx, New York, United States
- Oregon Health and Sciences University, Portland, Oregon, United States
- University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States
- Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, United States
- National Taiwan University Cancer Center, Taipei, Taiwan
Other microbiome trials you might be interested in
Hepatocellular Carcinoma
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combine…
Nanjing, ChinaEst. completion Sep 2031
HCC - Hepatocellular Carcinoma
Real-world data from a single-center experience evaluating patients with hepatocellular carcinoma (HCC) receiving system…
Al Mansurah, EgyptEst. completion Dec 15, 2027